Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles.
The importance of cholesterol for endocytosis has been investigated in HEp-2 and other cell lines by using methyl-beta-cyclodextrin (MbetaCD) to selectively extract cholesterol from the plasma membrane. MbetaCD treatment strongly inhibited endocytosis of transferrin and EGF, whereas endocytosis of ricin was less affected. The inhibition of transferrin endocytosis was completely reversible. On removal of MbetaCD it was restored by continued incubation of the cells even in serum-free medium. The recovery in serum-free medium was inhibited by addition of lovastatin, which prevents cholesterol synthesis, but endocytosis recovered when a water-soluble form of cholesterol was added together with lovastatin. Electron microscopical studies of MbetaCD-treated HEp-2 cells revealed that typical invaginated caveolae were no longer present. Moreover, the invagination of clathrin-coated pits was strongly inhibited, resulting in accumulation of shallow coated pits. Quantitative immunogold labeling showed that transferrin receptors were concentrated in coated pits to the same degree (approximately sevenfold) after MbetaCD treatment as in control cells. Our results therefore indicate that although clathrin-independent (and caveolae-independent) endocytosis still operates after removal of cholesterol, cholesterol is essential for the formation of clathrin-coated endocytic vesicles.
Rodal
S K
SK
Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway.
Skretting
G
G
Garred
O
O
Vilhardt
F
F
van Deurs
B
B
Sandvig
K
K
D000818:Animals; D002460:Cell Line; D002784:Cholesterol / Q000302:isolation & purification / Q000502:physiology*; D002966:Clathrin / Q000187:drug effects / Q000502:physiology*; D003505:Cyclodextrins / Q000494:pharmacology*; D004285:Dogs; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D011992:Endosomes / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D006801:Humans; D007668:Kidney; D007700:Kinetics; D008563:Membrane Lipids / Q000502:physiology; D011990:Receptors, Transferrin / Q000235:genetics / Q000502:physiology*; D011994:Recombinant Proteins / Q000378:metabolism; D012276:Ricin / Q000493:pharmacokinetics; D014162:Transfection; D014168:Transferrin / Q000493:pharmacokinetics*; D014407:Tumor Cells, Cultured; D047392:beta-Cyclodextrins
D002966:Clathrin; D003505:Cyclodextrins; D008563:Membrane Lipids; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D014168:Transferrin; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D012276:Ricin; D002784:Cholesterol